Skip to content

Neurocrine Biosciences Inc (NBIX) stock: revenue, earnings & dividend

Neurocrine Biosciences Inc (NBIX, Nasdaq): revenue, earnings, dividend and balance sheet from official SEC filings.

Stock screener NBIX · Nasdaq Pharma & Biotech US-CA

Key figures

Fiscal year
2025
Revenue
2.86 bn $
Revenue growth
21.5 %
Revenue growth 5y (p.a.)
22.3 %
Net income
479 m $
Net margin
16.7 %
Operating margin
21.6 %
Earnings per share (diluted)
4.67 $
Dividend per share
–
Payout ratio
–
Consecutive dividend years
–
Consecutive dividend raises
–
Dividend growth 5y (p.a.)
–
Total assets
4.63 bn $
Equity
3.25 bn $
Equity ratio
70.2 %
Return on equity
14.7 %
Cash
713 m $
Operating cash flow
783 m $
Free cash flow
749 m $
Shares outstanding
101,218,643

History

Revenue by fiscal year

2016 15 m $
2017 162 m $
2018 451 m $
2019 788 m $
2020 1.05 bn $
2021 1.13 bn $
2022 1.49 bn $
2023 1.89 bn $
2024 2.36 bn $
2025 2.86 bn $

Net income by fiscal year

2016 -141.09 m $
2017 -142.54 m $
2018 21.1 m $
2019 37 m $
2020 407 m $
2021 89.6 m $
2022 155 m $
2023 250 m $
2024 341 m $
2025 479 m $
YearRevenueNet incomeEPSDividend per shareOperating cash flow
20252.86 bn $479 m $4.67 $–783 m $
20242.36 bn $341 m $3.29 $–595 m $
20231.89 bn $250 m $2.47 $–390 m $
20221.49 bn $155 m $1.56 $–339 m $
20211.13 bn $89.6 m $0.92 $–257 m $
20201.05 bn $407 m $4.16 $–229 m $
2019788 m $37 m $0.39 $–147 m $
2018451 m $21.1 m $0.22 $–101 m $
2017162 m $-142.54 m $-1.62 $–-94.33 m $
201615 m $-141.09 m $-1.63 $–-106.18 m $

Data from XBRL filings at the SEC, processed automatically, no guarantee. Not investment advice. All filings at the SEC (EDGAR)